Drug Trial Radar · NCT03911388
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 12, 2019
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cannonball Kids' Cancer Foundation; Treovir, Inc
- First posted
- Apr 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 36 months, up to 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Conditions
- Neoplasms, Brain
- Glioblastoma Multiforme
- Glioblastoma of Cerebellum
- Neoplasms
- Astrocytoma
- Astrocytoma, Cerebellar
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Cerebellar PNET, Childhood
- Cerebellar Neoplasms
- Cerebellar Neoplasms, Primary
- Cerebellar Neoplasm, Malignant
- Cerebellar Neoplasm Malignant Primary
- Neoplasm Metastases
- Neoplasm Malignant
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms, Primary
- Central Nervous System Neoplasms, Malignant
- Nervous System Neoplasms
- Neoplasms by Site
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Medulloblastoma Recurrent
- HSV
- Virus
- Pediatric Brain Tumor
- Nervous System Cancer
- Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
G207Biological
Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse EventsTime frame: Baseline to 15 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Siteman Cancer Center at Washington University
St Louis, Missouri · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.